January 23rd 2024
Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
December 26th 2023
Online Support Tools Teach Self-Management for Teens With Juvenile Arthritis
November 16th 2016At the Annual Meeting of the American College of Rheumatology in Washington, DC, several experts presented their progress in harnessing technology to help teenagers and young adults manage their juvenile arthritis.
Read More
Genes, the Environment, and Autoimmune Disease
November 14th 2016David Hafler, MD, chairman of the Department of Neurology at the Yale School of Medicine, spoke of exciting times in the field of genome-wide association study-specifically speaking to neurology, genetics, the environment, and the autoimmune response.
Read More
Reconsidering the Economic Value of Multiple Sclerosis Therapies
Availability of multiple sclerosis (MS) therapies provides substantial value to the currently healthy (who may contract MS in the future), particularly when treatment is fully covered by insurance.
Read More
OOP Expenses Remain a Problem in Medicare, Especially for Beneficiaries Taking Specialty Drugs
October 11th 2016Medicare beneficiaries still face huge out-of-pocket expenses because of uncapped cost sharing in the catastrophic coverage phase. This is especially true for beneficiaries who take specialty drugs.
Read More
What We're Reading: Anthem Will Not Cover First Drug Approved for Duchenne
October 10th 2016What we're reading, October 10, 2016: Anthem will not cover Exondys 51, the first drug approved for treatment of Duchenne muscular dystrophy; big soda has sponsored 96 health and medical groups; and new Illinois program seeks to fill care gaps for working poor.
Read More
Jakafi Named Recommended Treatment for Myelofibrosis in NCCN Guideline
October 9th 2016As part of the National Comprehensive Cancer Network's new clinical guidelines for myeloproliferative neoplasms, a group of rare blood cancers, Jakafi has been recommended for the treatment of myelofibrosis.
Read More
Specialty Pharmaceutical Pipeline: Increased Competition, Biosimilar Uncertainty
October 4th 2016Perennial favorite, Aimee Tharaldson, PharmD, senior clinical consultant of emerging therapeutics at Express Scripts, opened the Academy of Managed Care Pharmacy 2016 Nexus, October 3, 2016, in National Harbor, Maryland, with a discussion of specialty pharmaceutical drugs in the pipeline.
Read More
What We're Reading: Government Wants Clinical Trial Findings More Widely Available
September 19th 2016What we're reading, September 19, 2016: the government update rules on reporting clinical trial findings; hospitals say they aren't receiving discounts for Valeant's heart drugs; and the FDA approved the first treatment for Duchenne muscular dystrophy.
Read More